ORGENESIS INC COM USD0.001 (ORGS)

0.41
OTC Markets
Prev Close 0.41
Day Low/High 0.34 / 0.41
52 Wk Low/High 0.24 / 0.52
Exchange OTC Markets
Shares Outstanding 110.73B
Market Cap 45.95M
Div & Yield N.A. (N.A)

Orgenesis And ATMI Enter Into Process Development Agreement

Orgenesis Novel Therapeutic Technology Enabled by ATMI Investment and Bioreactor Technology

Orgenesis Appoints Leading Diabetes Expert, Camillo Ricordi, M.D., To Scientific Advisory Board

Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Meets With The Paul-Ehrlich Institute

Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Enters Into R&D Agreement With The Fraunhofer IGB

Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Presents Technology Update To FDA/CBER Experts

Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis To Sponsor And Present At ESGCT 20th Anniversary Congress

Orgenesis Inc. (ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Spotlighted In August 2012 Issue Of Drug Discovery News

Orgenesis Inc. (OTCBB: ORGS) (“Orgenesis” or “the Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Chief Science Officer Describes Science In Two Online Publications

Orgenesis Inc. (OTCBB: ORGS) (“Orgenesis” or “the Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Inc. Announces Definitive Agreement To Acquire Autologous Insulin Producing Cells (AIPC) Regeneration Technology.

Orgenesis Inc., ( OTCBB: ORGS) (the “Company”) announced today that pursuant to a licensing agreement dated February 2, 2012 with Tel Hashomer - Medical Research, Infrastructure and Services Ltd.